Strategies for AE Management with Tucatinib in Breast Cancer

Opinion
Video

Heather Moore, CPP, PharmD, shares expert insights on the effective management of adverse effects related to tucatinib and other HER2 tyrosine kinase inhibitors (TKIs).

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content